Publication: 2879

Publication: 2879

PHASE I-II TRIAL OF IMATINIB MESYLATE (GLEEVEC; STI571) IN TREATMENT OF RECURRENT OLIGODENDROGLIOMA AND MIXED OLIGOASTROCYTOMA. NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0272 (ALLIANCE/NCCTG)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: J Neurooncol vol 143 (3) 573-581

Year:: 2019
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 8

Parents:: 641
Children:: None

Program:: OGC
Primary Committee:: Neuro-Onc
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U10CA180790, U10CA180844, UG1CA189863, U24CA196171

Corr. Author:
Authors:: Kurt A. Jaeckle S K. Anderson Erin L. Twohy Jesse G. Dixon Caterina Giannini Robert Jenkins Merrill J. Egorin Jann N. Sarkaria Paul D. Brown P J. Flynn John Schwerkoske Jan C. Buckner Eva Galanis

Networks:: LAPS-MN026, METROMIN, MN017

Study: NCCTG-N0272
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 1/2

Keywords:: oligodendroglioma, imatinib, NCCTG, Alliance, N0272, PDGF